The LynxDx leadership team. In the front row (from left to right) are: Spencer Heaton, Chief Medical and Commercial Officer; Steve Riggs, President; and Jeff Crays, Chief Technology Officer. In the ...

Prostate cancer is the second most common form of cancer found in men worldwide, affecting one out of nine at some point in their lives. It’s also the second leading cause of cancer death among men in ...

Prostate cancer is the second most common cancer in men, with over 288,000 new cases diagnosed each year. It is also one of the most curable cancers if detected early. A new imaging tool is helping ...

A new study from the UK has suggested a new way to “significantly” reduce prostate cancer deaths. It says that a simple, 10-minute MRI (Magnetic Resonance Imaging) scan can pick up more early-stage ...

If you or a loved one are navigating the journey of prostate cancer, you know that every decision weighs heavily. You’ve likely faced surgery or initial treatments, only to encounter the fear that ...

The FDA has granted premarket approval (PMA) to the IsoPSA test, a novel, blood-based in vitro diagnostic kit designed to assist clinicians in deciding whether to proceed with prostate biopsy in men ...

SAN DIEGO -- An algorithm-based decision tool eliminated inappropriate prescribing of bone-modifying agents (BMA) in patients with advanced prostate cancer, according to a VA-based study. Prior to ...

In the month of October, many organizations use the color pink to raise awareness for breast cancer. Women are encouraged to do regular home exams and to attend their annual mammograms. For men, ...

Prostate cancer remains the second most common form of cancer found in men worldwide and is the second leading cause of cancer death among men in the U.S. Screening for prostate cancer can help to ...